Access Vascular was founded in 2015 to address the most common and costly complications of intravenous therapy: infection, thrombosis and phlebitis. The company is developing a suite of venous access devices made from patented biomaterials which are highly biocompatible and are capable of long-term thrombus resistance.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/03/21 | $20,000,000 | Series B |
TVM Capital Life Science | undisclosed |
| 10/31/23 | $22,000,000 | Series C |
